(Total Views: 371)
Posted On: 01/13/2017 11:24:19 AM
Post# of 11
NEOS (MC $91 M) $60 M Cash 1 Drug approved /2 Drugs close to FDA approval targeting Billion Dollar Markets .
Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $91 M
Cash: $60 M
Price $5.90
Shares Out: 16.06 M
Presentation
http://investors.neostx.com/phoenix.zhtml?c=2...sentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $91 M
Cash: $60 M
Price $5.90
Shares Out: 16.06 M
Presentation
http://investors.neostx.com/phoenix.zhtml?c=2...sentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
(0)
(0)
